{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T06:01:12Z","timestamp":1782280872707,"version":"3.54.5"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/100006259","name":"Teva Pharmaceutical Industries","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006259","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neuroinflammation"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12974-017-0945-z","type":"journal-article","created":{"date-parts":[[2017,8,31]],"date-time":"2017-08-31T02:40:21Z","timestamp":1504147221000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Safety and in vivo immune assessment of escalating doses of oral laquinimod in patients with RRMS"],"prefix":"10.1186","volume":"14","author":[{"given":"Tjalf","family":"Ziemssen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayrettin","family":"Tumani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony","family":"Sehr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friedemann","family":"Paul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nils","family":"Richter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emil","family":"Samara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ofer","family":"Spiegelstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ella","family":"Sorani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oren","family":"Bar-Ilan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorit","family":"Mimrod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liat","family":"Hayardeny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,8,31]]},"reference":[{"key":"945_CR1","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1021\/jm031044w","volume":"47","author":"S Jonsson","year":"2004","unstructured":"Jonsson S, Andersson G, Fex T, et al. Synthesis and biological evaluation of new 1,2-dihydro-4-hydroxy-2-oxo-3 quinolinecarboxamides for treatment of autoimmune disorders: structure\u2013activity relationship. J Med Chem. 2004;47:2075\u201388.","journal-title":"J Med Chem"},{"key":"945_CR2","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1056\/NEJMoa1104318","volume":"366","author":"G Comi","year":"2012","unstructured":"Comi G, Jeffery D, Kappos L, Montalban X, Boyko A, Rocca M, Filippi M, for the ALLEGRO Study Group. Placebo-controlled trial of oral laquinimod for multiple sclerosis. N Engl J Med. 2012;366:1000\u20139.","journal-title":"N Engl J Med"},{"key":"945_CR3","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1007\/s00415-014-7264-4","volume":"261","author":"TL Vollmer","year":"2014","unstructured":"Vollmer TL, Sorensen PS, Selmaj K, Zipp F, Havrdova E, Cohen JA, Sasson N, Gilgun-Sherki Y, Arnold DL, for the BRAVO Study Group. A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis. J Neurol. 2014;261:773\u201383.","journal-title":"J Neurol"},{"key":"945_CR4","unstructured":"Teva and Active Biotech Announce Concerto trial of laquinimod in RRMS did not meet primary endpoint. \nhttp:\/\/www.tevapharm.com\/news\/teva_and_active_biotech_announce_concerto_trial_of_laquinimod_in_rrms_did_not_meet_primary_endpoint_05_17.aspx\n\n. Accessed 21 Aug 2017."},{"key":"945_CR5","unstructured":"A phase 2 clinical study in subjects with primary progressive multiple sclerosis to assess the efficacy, safety and tolerability of two oral doses of laquinimod either of 0.6 mg\/day or 1.5 mg\/day (experimental drug) as compared to placebo. Registered on Clinical  trials.gov  . \nhttps:\/\/clinicaltrials.gov\/ct2\/show\/NCT02284568\n\n. Accessed 21 Aug 2017."},{"key":"945_CR6","unstructured":"A clinical study in subjects with huntington\u2019s disease to assess the efficacy and safety of three oral doses of laquinimod (LEGATO-HD). \nhttps:\/\/clinicaltrials.gov\/ct2\/show\/NCT02215616\n\n. Accessed 21 Aug 2017."},{"key":"945_CR7","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0165-5728(02)00225-4","volume":"130","author":"C Brunmark","year":"2002","unstructured":"Brunmark C, Runstr\u00f6m A, Ohlsson L, Sparre B, Brodin T, Astrom M, Hedlund G. The new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental allergic encephalomyelitis. J Neuroimmunol. 2002;130:163\u201372.","journal-title":"J Neuroimmunol"},{"key":"945_CR8","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jns.2011.02.019","volume":"306","author":"W Br\u00fcck","year":"2011","unstructured":"Br\u00fcck W, Wegner C. Insight into the mechanism of laquinimod action. J Neurol Sci. 2011;306:173\u20139.","journal-title":"J Neurol Sci"},{"key":"945_CR9","doi-asserted-by":"crossref","first-page":"e272","DOI":"10.1212\/NXI.0000000000000272","volume":"21","author":"M Varrin-Doyer","year":"2016","unstructured":"Varrin-Doyer M, Pekarek KL, Spencer CM, Bernard CCA, Sobel RA, Cree B, Schulze-Topphoff U, Zamvil S. Treatment of spontaneous EAE by laquinimod reduces Tfh, B cell aggregates, and disease progression. Neurol Neuroimmunol Neuroinflamm. 2016;21:e272.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"945_CR10","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S0028-3908(02)00015-1","volume":"42","author":"LP Zou","year":"2002","unstructured":"Zou LP, Abbas N, Volkmann I, Nennesmo I, Levi M, Wahren B, Winblad B, Hedlund G, Zhu J. Suppression of experimental autoimmune neuritis by ABR-215062 is associated with altered Th1\/Th2 balance and inhibited migration of inflammatory cells into the peripheral nerve tissue. Neuropharmacology. 2002;42:731\u20139.","journal-title":"Neuropharmacology"},{"key":"945_CR11","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jneuroim.2004.02.016","volume":"156","author":"JS Yang","year":"2004","unstructured":"Yang JS, Xu LY, Xiao BG, Hedlund G, Link H. Laquinimod (ABR-215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1\/Th2 balance and induces the Th3 cytokine TGF-beta in Lewis rats. J Neuroimmunol. 2004;156:3\u20139.","journal-title":"J Neuroimmunol"},{"key":"945_CR12","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jneuroim.2010.07.009","volume":"227","author":"C Wegner","year":"2010","unstructured":"Wegner C, Stadelmann C, Pf\u00f6rtner R, Raymond E, Feigelson S, Alon R, Timan B, Hayardeny L, Bruck W. Laquinimod interferes with migratory capacity of T cells and reduces IL-17 levels, inflammatory demyelination and acute axonal damage in mice with experimental autoimmune encephalomyelitis. J Neuroimmunol. 2010;227:133\u201343.","journal-title":"J Neuroimmunol"},{"key":"945_CR13","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/brb3.174","volume":"3","author":"S Moore","year":"2013","unstructured":"Moore S, Khalaj AJ, Yoon J, Patel R, Hannsun G, Yoo T, Sasidhar M, Martinez-Torres L, Hayardeny L, Tiwari-Woodruff SK. Therapeutic laquinimod treatment decreases inflammation, initiates axon remyelination, and improves motor deficit in a mouse model of multiple sclerosis. Brain Behav. 2013;3:664\u201382.","journal-title":"Brain Behav"},{"key":"945_CR14","doi-asserted-by":"publisher","first-page":"e33797","DOI":"10.1371\/journal.pone.0033797","volume":"7","author":"U Schulze-Topphoff","year":"2012","unstructured":"Schulze-Topphoff U, Shetty A, Varrin-Doyer M, Molnarfi N, Sagan SA, Sobel RA, Nelson PA, Zamvil SS. Laquinimod, a quinoline-3-carboxamide, induces type II myeloid cells that modulate central nervous system autoimmunity. PLoS ONE. 2012;7:e33797. \nhttps:\/\/doi.org\/10.1371\/journal.pone.0033797\n\n.","journal-title":"PLoS ONE"},{"key":"945_CR15","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1007\/s11940-015-0354-5","volume":"17","author":"J D\u00f6rr","year":"2015","unstructured":"D\u00f6rr J, Paul F. The transition from first-line to second-line therapy in multiple sclerosis. Curr Treat Options Neurol. 2015;17:354.","journal-title":"Curr Treat Options Neurol"},{"key":"945_CR16","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/j.1600-0404.2008.01036.x","volume":"188","author":"O Torkildsen","year":"2008","unstructured":"Torkildsen O, Brunborg LA, Myhr KM, Bo L. The cuprizone model for demyelination. Acta Neurol Scand Suppl. 2008;188:72\u20136.","journal-title":"Acta Neurol Scand Suppl"},{"key":"945_CR17","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s00401-012-1009-1","volume":"124","author":"W Br\u00fcck","year":"2012","unstructured":"Br\u00fcck W, Pf\u00f6rtner R, Pham T, Zhang J, Hayardeny L, Piryatinsky V, Hanisch UK, Regen T, van Rossum D, Brakelmann L, Hagemeier K, Kuhlmann T, Stadelmann C, John GR, Kramman N, Wegner C. Reduced astrocytic NF-kB activation by laquinimod protects from cuprizone-induced demyelination. Acta Neuropathol. 2012;124:411\u201324.","journal-title":"Acta Neuropathol"},{"key":"945_CR18","doi-asserted-by":"crossref","first-page":"e233","DOI":"10.1212\/NXI.0000000000000233","volume":"17","author":"N Kramann","year":"2016","unstructured":"Kramann N, Menken L, Hayardeny L, Hanisch U-K, Bruck W. Laquinimod prevents cuprizone-induced demyelination independent of Toll-like receptor signalling. Neurol Neuroimmunol Neuroinflamm. 2016;17:e233.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"945_CR19","doi-asserted-by":"crossref","first-page":"E6145","DOI":"10.1073\/pnas.1607843113","volume":"113","author":"J Kaye","year":"2016","unstructured":"Kaye J, Piryatinsky V, Birnberg T, Hingaly T, Raymond E, Kashi R, Amit-Romach E, Caballero IS, Towfic F, Ator MA, Runbinstein E, Laifenfield D, Orbach A, Shinar D, Marantz Y, Grossman I, Knappertz V, Hayden MR, Laufer R. Laquinimod arrests experimental autoimmune encephalomyelitis by activating the aryl hydrocarbon receptor. PNAS. 2016;113:E6145\u201352.","journal-title":"PNAS"},{"key":"945_CR20","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.jneuroim.2013.07.008","volume":"263","author":"BT Lund","year":"2013","unstructured":"Lund BT, Kelland EE, Hayardeny L, Bar Ilan O, Gilmore W, Weiner LP. Assessment of changes in immune measures of multiple sclerosis patients treated with laquinimod. J Neuroimmunol. 2013;263:108\u201315.","journal-title":"J Neuroimmunol"},{"key":"945_CR21","doi-asserted-by":"crossref","unstructured":"Stasiolek M, Linker RA, Hayardeny L, Bar Ilan O, Gold R. Immune parameters of patients treated with laquinimod, a novel oral therapy for the treatment of multiple sclerosis: results from a double-blind placebo-controlled study. Immun Inflamm Dis. 2015;3:45\u20135.","DOI":"10.1002\/iid3.42"},{"key":"945_CR22","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1093\/brain\/awt023","volume":"136","author":"V Jolivel","year":"2013","unstructured":"Jolivel V, Luessi F, Masri J, Kraus SH, Hubo M, Poisa-Beiro L, Klebow S, Paterka M, Yogey N, Tumani H, Furlan R, Siffrin V, Jonuleit H, Zipp F, Waisman A. Modulation of dendritic cell properties by laquinimod as a mechanism for modulating multiple sclerosis. Brain. 2013;136:1048\u201366.","journal-title":"Brain"},{"key":"945_CR23","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.1212\/NXI.0000000000000033","volume":"1","author":"K Thomas","year":"2014","unstructured":"Thomas K, Dietze K, Wehner R, Metz I, Wehner K, Dietze K, Wehner R, Metz I, Tumani H, Schulthei\u00df T, G\u00fcnther C, Sch\u00e4kel K, Reichmann H, Br\u00fcck W, Schmitz M, Ziemssen T. Accumulation and therapeutic modulation of 6-sulfo LacNAc(+) dendritic cells in multiple sclerosis. Neurol Neuroimmunol Neuroinflamm. 2014;1:e33.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"945_CR24","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/j.1365-2567.2010.03336.x","volume":"132","author":"M Gschwandtner","year":"2011","unstructured":"Gschwandtner M, Sch\u00e4kel K, Werfel T, Gutzmer R. Histamine H(4) receptor activation on human slan-dendritic cells down-regulates their pro-inflammatory capacity. Immunology. 2011;132:49\u201356.","journal-title":"Immunology"},{"key":"945_CR25","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/nan.12313","volume":"42","author":"K Thomas","year":"2016","unstructured":"Thomas K, Metz I, Tumani H, Br\u00fcck W, Ziemssen T. 6-sulfo LacNAc(+) dendritic cells accumulate in various inflammatory, but not ischemic conditions of the central nervous system. Neuropathol Appl Neurobiol. 2016;42:394\u20138.","journal-title":"Neuropathol Appl Neurobiol"},{"key":"945_CR26","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/ana.20703","volume":"58","author":"CH Polman","year":"2005","unstructured":"Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, Lublin F, Metz L, McFarland H, O\u2019Connor P, Sandberg-Wollheim M, Thompson A, Weinshenker B, Wolinsky J. Diagnostic criteria for multiple sclerosis: 2005 revisions to the \u201cMcDonald Criteria\u201d. Ann Neurol. 2005;58:840\u20136.","journal-title":"Ann Neurol"},{"key":"945_CR27","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","volume":"33","author":"JF Kurtzke","year":"1983","unstructured":"Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33:1444\u201352.","journal-title":"Neurology"},{"key":"945_CR28","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1093\/brain\/awh163","volume":"127","author":"MS Weber","year":"2004","unstructured":"Weber MS, Starck M, Wagenpfeil S, Meinl E, Hohlfeld R, Farina C. Multiple sclerosis: glatiramer acetate inhibits monocyte reactivity in vitro and in vivo. Brain. 2004;127:1370\u20138.","journal-title":"Brain"},{"key":"945_CR29","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1038\/nm1620","volume":"13","author":"MS Weber","year":"2007","unstructured":"Weber MS, Prod\u2019homme T, Youssef S, Dunn SE, Rundle CD, Lee L, Patarroyo JC, St\u00fcve O, Sobel RA, Steinman L, Zamvil SS. Type II monocytes modulate T cell-mediated central nervous system autoimmune disease. Nat Med. 2007;13:935\u201343.","journal-title":"Nat Med"},{"key":"945_CR30","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1002\/eji.200425556","volume":"35","author":"H Muller","year":"2005","unstructured":"Muller H, Hofer S, Kaneider N, Neuwirt H, Mosheimer B, Mayer G, Konwalinka G, Heufler C, Tiefenthaler M. The immunomodulator FTY720 interferes with effector functions of human monocyte-derived dendritic cells. Eur J Immunol. 2005;35:533\u201345.","journal-title":"Eur J Immunol"},{"key":"945_CR31","doi-asserted-by":"publisher","unstructured":"Thomas K, Sehr T, Proschmann U, Rodriguez-Leal FA, Haase R, Ziemssen T. Fingolimod additionally acts as immunomodulator focused on the innate immune system beyond its prominent effects on lymphocyte recirculation. J Neuroinflammation. 2017. DOI \nhttps:\/\/doi.org\/10.1186\/s12974-017-0817-6\n\n.","DOI":"10.1186\/s12974-017-0817-6"},{"key":"945_CR32","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1084\/jem.20100977","volume":"208","author":"K Ghoreschi","year":"2011","unstructured":"Ghoreschi K, Br\u00fcck J, Kellerer C, Deng C, Peng H, Rothfuss O, Hussain RZ, Gocke AR, Respa A, Glocova I, Valtcheva N, Alexander E, Feil S, Schulze-Osthoff K, Rupec RA, Lovett-Racke AE, Dringen R, Racke MK, R\u00f6cken M. Fumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cells. J Exp Med. 2011;208:2291\u2013303.","journal-title":"J Exp Med"}],"container-title":["Journal of Neuroinflammation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12974-017-0945-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,8,31]],"date-time":"2017-08-31T02:40:42Z","timestamp":1504147242000},"score":1,"resource":{"primary":{"URL":"http:\/\/jneuroinflammation.biomedcentral.com\/articles\/10.1186\/s12974-017-0945-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,31]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["945"],"URL":"https:\/\/doi.org\/10.1186\/s12974-017-0945-z","relation":{},"ISSN":["1742-2094"],"issn-type":[{"value":"1742-2094","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,31]]},"article-number":"172"}}